The biotech is acquiring Clade Therapeutics and its stem cell technology at a discount price, while adding $60 million via a private placement led by Bain Capital.
Century is pursuing additional autoimmune disease regulatory filings for its iPSC derived iNK cell therapy, CNTY-101, beyond CALiPSO-1 trial in SLE, based on the potential of its differentiated...
Clade Therapeutics, which is developing off-the-shelf cell therapies, has dismissed a number of staffers in the US and Europe, according to social media posts made by employees and a top executive at the company.
Expands Clade™s pipeline and broadens its platform with:- proprietary gamma/delta (g/d) TCR universal targeting platform technology,- g/d TCR candidate integrated into Clade™s solid tumor pipeline ...
CAMBRIDGE, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Clade Therapeutics, a biopharmaceutical company focused on discovering and delivering scalable, off-the-shelf, next-generation stem cell-based...